Literature DB >> 12744087

Human tumor cells are selectively inhibited by colicins.

J Chumchalová1, J Smarda.   

Abstract

The activity in vitro of four types of colicins (A, E1, E3, U) against one human standard fibroblast line and against 11 human tumor-cell lines carrying defined mutations of the p53 gene was quantified by MTT (tetrazolium bromide) assay. Flow cytometry showed that the pore-forming colicins A, E1 and U affected the cell cycle of 5 of these cell lines. Colicins E3 and U did not show any distinct inhibitory effects on the cell lines, while colicins E1 and especially A inhibited the growth of all of them (with one exception concerning colicin E1). Colicin E1 inhibited the growth of the tumor lines by 17-40% and standard fibroblasts MRC5 by 11%. Colicin A exhibited a differentiated 16-56% inhibition, the growth of standard fibroblasts being inhibited by 36%. In three of the lines, colicins A and E1 increased the number of cells in the G1 phase (by 12-58%) and in apoptosis (by 7-58%). These results correlated with the data from sensitivity assays. Hence, the inhibitory effect of colicins on eukaryotic cells in cell-selective, colicin-specific and can be considered to be cytotoxic.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12744087     DOI: 10.1007/BF02931286

Source DB:  PubMed          Journal:  Folia Microbiol (Praha)        ISSN: 0015-5632            Impact factor:   2.629


  16 in total

1.  Cytotoxic effects of colicins E1 and E3 on v-myb-transformed chicken monoblasts.

Authors:  J Smarda; M Fialová; J Smarda
Journal:  Folia Biol (Praha)       Date:  2001       Impact factor: 0.906

2.  Production of bacteriocins by different enterococcal isolates.

Authors:  A Lauková; M Mareková
Journal:  Folia Microbiol (Praha)       Date:  2001       Impact factor: 2.099

3.  Binding domains of colicins E1, E2 and E3 in the receptor protein BtuB of Escherichia coli.

Authors:  J Smarda; L Macholán
Journal:  Folia Microbiol (Praha)       Date:  2000       Impact factor: 2.099

4.  Translocation of colicin from the receptor to the inner cell membrane: function of the peptidoglycan layer.

Authors:  J Smarda; P Matĕjková; A Vavrícková
Journal:  Folia Microbiol (Praha)       Date:  2002       Impact factor: 2.099

Review 5.  p53, the cellular gatekeeper for growth and division.

Authors:  A J Levine
Journal:  Cell       Date:  1997-02-07       Impact factor: 41.582

6.  Bacteriocin receptors on malignant mammalian cells: are they transferrin receptors?

Authors:  H Farkas-Himsley; C E Musclow
Journal:  Cell Mol Biol       Date:  1986       Impact factor: 1.770

Review 7.  The cell cycle: a review.

Authors:  K A Schafer
Journal:  Vet Pathol       Date:  1998-11       Impact factor: 2.221

8.  Effect of a bacteriocin produced by Mycobacterium smegmatis on growth of cultured tumor and normal cells.

Authors:  H Saito; T Watanabe
Journal:  Cancer Res       Date:  1979-12       Impact factor: 12.701

9.  Acute lymphoblastic leukemia of childhood monitored by bacteriocin and flowcytometry.

Authors:  C E Musclow; H Farkas-Himsley; S S Weitzman; M Herridge
Journal:  Eur J Cancer Clin Oncol       Date:  1987-04

10.  Studies of colicin action on wall-less stable L-forms of Escherichia coli. I. Degree of attachment and of killing effect on rods and stable L-form cells.

Authors:  J Smarda; E Schuhmann
Journal:  Z Allg Mikrobiol       Date:  1979
View more
  23 in total

Review 1.  The bacterial instrument as a promising therapy for colon cancer.

Authors:  Atieh Yaghoubi; Majid Khazaei; Amir Avan; Seyed Mahdi Hasanian; Saman Soleimanpour
Journal:  Int J Colorectal Dis       Date:  2020-03-04       Impact factor: 2.571

2.  RNase/anti-RNase activities of the bacterial parD toxin-antitoxin system.

Authors:  Ana J Muñoz-Gómez; Marc Lemonnier; Sandra Santos-Sierra; Alfredo Berzal-Herranz; Ramón Díaz-Orejas
Journal:  J Bacteriol       Date:  2005-05       Impact factor: 3.490

3.  Bacteriocinogeny in experimental pigs treated with indomethacin and Escherichia coli Nissle.

Authors:  Jan Bures; David Smajs; Jaroslav Kvetina; Miroslav Förstl; Jan Smarda; Darina Kohoutova; Martin Kunes; Jiri Cyrany; Ilja Tacheci; Stanislav Rejchrt; Jirina Lesna; Viktor Vorisek; Marcela Kopacova
Journal:  World J Gastroenterol       Date:  2011-02-07       Impact factor: 5.742

4.  Bacteriocin synthesis in uropathogenic and commensal Escherichia coli: colicin E1 is a potential virulence factor.

Authors:  David Smajs; Lenka Micenková; Jan Smarda; Martin Vrba; Alena Sevčíková; Zuzana Vališová; Vladana Woznicová
Journal:  BMC Microbiol       Date:  2010-11-15       Impact factor: 3.605

Review 5.  Antibacterial activities of bacteriocins: application in foods and pharmaceuticals.

Authors:  Shih-Chun Yang; Chih-Hung Lin; Calvin T Sung; Jia-You Fang
Journal:  Front Microbiol       Date:  2014-05-26       Impact factor: 5.640

6.  Escherichia coli strains of phylogenetic group B2 and D and bacteriocin production are associated with advanced colorectal neoplasia.

Authors:  Darina Kohoutova; David Smajs; Paula Moravkova; Jiri Cyrany; Monika Moravkova; Miroslava Forstlova; Michal Cihak; Stanislav Rejchrt; Jan Bures
Journal:  BMC Infect Dis       Date:  2014-12-24       Impact factor: 3.090

7.  Anticancer properties of a defensin like class IId bacteriocin Laterosporulin10.

Authors:  Piyush Baindara; Ankur Gautam; G P S Raghava; Suresh Korpole
Journal:  Sci Rep       Date:  2017-04-19       Impact factor: 4.379

Review 8.  Colorectal cancer treatment using bacteria: focus on molecular mechanisms.

Authors:  Sara Ebrahimzadeh; Hossein Ahangari; Alireza Soleimanian; Kamran Hosseini; Vida Ebrahimi; Tohid Ghasemnejad; Saiedeh Razi Soofiyani; Vahideh Tarhriz; Shirin Eyvazi
Journal:  BMC Microbiol       Date:  2021-07-19       Impact factor: 3.605

Review 9.  Bacteriocins as Potential Anticancer Agents.

Authors:  Sumanpreet Kaur; Sukhraj Kaur
Journal:  Front Pharmacol       Date:  2015-11-10       Impact factor: 5.810

10.  Bacteriocin-encoding genes and ExPEC virulence determinants are associated in human fecal Escherichia coli strains.

Authors:  Lenka Micenková; Barbora Štaudová; Juraj Bosák; Lenka Mikalová; Simona Littnerová; Martin Vrba; Alena Ševčíková; Vladana Woznicová; David Šmajs
Journal:  BMC Microbiol       Date:  2014-04-28       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.